A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer

LESSONS LEARNED. The maximum tolerated dose of the combination of linsitinib and irinotecan is linsitinib 450 mg daily on days 1–3 every 7 days and irinotecan 125 mg/m(2) days 1 and 8 of a 21‐day cycle. The adverse effects associated with the combination are not significantly increased beyond what i...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, S. Lindsey, Eckhardt, S. Gail, Diamond, Jennifer R., Messersmith, Wells A., Dasari, Arvind, Weekes, Colin D., Lieu, Christopher H., Kane, Madeline, Choon Tan, Aik, Pitts, Todd M., Leong, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292546/
https://www.ncbi.nlm.nih.gov/pubmed/30139840
http://dx.doi.org/10.1634/theoncologist.2018-0315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292546/
https://www.ncbi.nlm.nih.gov/pubmed/30139840
http://dx.doi.org/10.1634/theoncologist.2018-0315

Ejemplares similares